Neurocrine Biosciences stock outperformed the S&P 500 composite on July 31, 2025.
1 report, 1 independent
Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Neurocrine Biosciences stock outperformed the S&P 500 composite on July 31, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ZacksHere's What Key Metrics Tell Us About Neurocrine (NBIX) Q2 Earnings Neurocrine Biosciences (NBIX) reported $687.5 million in revenue for the quarter ended June 2025, representing a year-over-year inc